Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.

Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.

Provided is a liquid composition comprising a mixture of terpenes, at least one cannabinoid and an oil carrier. According to one embodiments, the mixture of terpenes comprises alpha-pinene, myrcene and caryophyllene and at least one additional terpene selected from the group consisting of limonene, terpinolene, linalool, geraniol, humulene, nerolidol, bisabolol and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, myrcene, caryophyllene, nerolidol and bisabolol, and at least one additional terpene selected from the group consisting of ocimene, limonene, linalool, and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, limonene, terpinolene and caryophyllene and optionally at least one additional terpene selected from the group consisting of beta-pinene, eucalyptol, geraniol and bisabolol, or combinations thereof.

Provided is a liquid composition comprising a mixture of terpenes, at least one cannabinoid and an oil carrier. According to one embodiments, the mixture of terpenes comprises alpha-pinene, myrcene and caryophyllene and at least one additional terpene selected from the group consisting of limonene, terpinolene, linalool, geraniol, humulene, nerolidol, bisabolol and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, myrcene, caryophyllene, nerolidol and bisabolol, and at least one additional terpene selected from the group consisting of ocimene, limonene, linalool, and combinations thereof. According to a further embodiment, the mixture of terpenes comprises alpha-pinene, limonene, terpinolene and caryophyllene and optionally at least one additional terpene selected from the group consisting of beta-pinene, eucalyptol, geraniol and bisabolol, or combinations thereof.

Compounds according to formula (I), where R is as defined herein, have anti-cancer properties.

Compounds according to formula (I), where R is as defined herein, have anti-cancer properties.

The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins, including groups of polymorphisms that may be used as a signature marker set for such uses, as well as nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins, including groups of polymorphisms that may be used as a signature marker set for such uses, as well as nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.